Spero Therapeutics Management
Management criteria checks 2/4
Spero Therapeutics' CEO is Sath Shukla, appointed in Aug 2023, has a tenure of 1.42 years. total yearly compensation is $2.02M, comprised of 25.9% salary and 74.1% bonuses, including company stock and options. directly owns 0.068% of the company’s shares, worth €39.83K. The average tenure of the management team and the board of directors is 1.9 years and 10.7 years respectively.
Key information
Sath Shukla
Chief executive officer
US$2.0m
Total compensation
| CEO salary percentage | 25.9% |
| CEO tenure | 1.4yrs |
| CEO ownership | 0.07% |
| Management average tenure | 1.9yrs |
| Board average tenure | 10.7yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$4m |
| Jun 30 2024 | n/a | n/a | US$17m |
| Mar 31 2024 | n/a | n/a | US$23m |
| Dec 31 2023 | US$2m | US$524k | US$23m |
| Sep 30 2023 | n/a | n/a | -US$2m |
| Jun 30 2023 | n/a | n/a | -US$10m |
| Mar 31 2023 | n/a | n/a | -US$27m |
| Dec 31 2022 | US$2m | US$478k | -US$46m |
| Sep 30 2022 | n/a | n/a | -US$102m |
| Jun 30 2022 | n/a | n/a | -US$113m |
| Mar 31 2022 | n/a | n/a | -US$103m |
| Dec 31 2021 | US$2m | US$441k | -US$90m |
Compensation vs Market: Sath's total compensation ($USD2.02M) is above average for companies of similar size in the German market ($USD462.70K).
Compensation vs Earnings: Sath's compensation has been consistent with company performance over the past year.
CEO
Sath Shukla (51 yo)
1.4yrs
Tenure
US$2,024,647
Compensation
Mr. Satyavrat Shukla, also known as Sath, C.F.A., has been President, Chief Executive Officer and Director at Spero Therapeutics, Inc. since August 1, 2023. He had been the Chief Financial Officer of Spero...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Chairman of the Board | 11.3yrs | US$2.39m | 0.43% € 249.3k | |
| President | 1.4yrs | US$2.02m | 0.068% € 39.8k | |
| Chief Operating Officer | 1.9yrs | US$1.44m | 0.12% € 72.2k | |
| CFO, Chief Business Officer & Treasurer | 1.4yrs | no data | 0.063% € 36.7k | |
| Chief Human Resource Officer | 3.2yrs | no data | no data |
1.9yrs
Average Tenure
48yo
Average Age
Experienced Management: 2HA's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Chairman of the Board | 11.3yrs | US$2.39m | 0.43% € 249.3k | |
| President | 1.4yrs | US$2.02m | 0.068% € 39.8k | |
| Independent Director | 7.5yrs | US$88.83k | 0.028% € 16.0k | |
| Independent Director | 11yrs | US$105.70k | 0.058% € 33.6k | |
| Scientific Advisors | 10.7yrs | no data | no data | |
| Clinical Advisor | 10.7yrs | no data | no data | |
| Scientific Advisor | no data | no data | no data | |
| Lead Independent Director | 9.3yrs | US$93.19k | 0.028% € 16.0k | |
| Clinical Advisor | 10.7yrs | no data | no data | |
| Scientific Advisor | no data | no data | no data | |
| Clinical Advisor | 10.7yrs | no data | no data | |
| Independent Director | 5.8yrs | US$73.20k | 0.028% € 16.0k |
10.7yrs
Average Tenure
58yo
Average Age
Experienced Board: 2HA's board of directors are seasoned and experienced ( 10.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/05 13:37 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Spero Therapeutics, Inc. is covered by 10 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Esther Lannie Hong | Berenberg |
| Jason Matthew Gerberry | BofA Global Research |
| Louise Chen | Cantor Fitzgerald & Co. |